Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies

Vaccine

Volumn 27, Issue 20, 2009, Pages 2689-2694

  Pírez, María Catalina ^a   Olivera, Ignacio ^a   Diabarboure, Hugo ^b   Montano, Alicia ^a   Barañano, Raúl ^c   Badía, Federica ^a   Bonnet, Marie Claude ^d  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b Laboratorios Clausen   (Uruguay)

^c Clínica Medilab   (Uruguay)

^d SANOFI PASTEUR   (France)

Author keywords

Antibody persistence; Oral polio vaccine; Seroprevalence; Vaccination coverage

Indexed keywords

ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; FEMALE; HUMAN; IMMUNITY; INFANT; MAJOR CLINICAL STUDY; MALE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SEROPREVALENCE; SEROTYPE; URUGUAY; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; SEROEPIDEMIOLOGIC STUDIES; URUGUAY; VACCINATION; YOUNG ADULT;

EID: 64649096457     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.042     Document Type: Article

References (36)

1. Progress towards global poliomyelitis eradication: preparation for the oral poliovirus vaccine cessation era. Wkly Epidemiol Rec 79 39 (2004) 349-355
2. Certification of poliomyelitis eradication-the Americas. MMWR 43 39 (1994) 720-722
3. Certification of poliomyelitis eradication. WHO Western Pacific Region, October 2000. Wkly Epidemiol Rec 75 49 (2000) 399-400
4. Certification of poliomyelitis eradication-European Region, June 2002. MMWR 51 26 (2002) 572-574
5. Pallansch M.A., and Sandhu H.S. The eradication of polio-progress and challenges. N Engl J Med 355 24 (2006) 2508-2511
6. Ministerio de Salud Pública Uruguay. Programa Ampliado de Inmunizaciones. http://www.msp.gub.uy. [Last accessed 6.10.2008].
7. Andrus J.K., Strebel P.M., de Quadros C.A., and Olive J.M. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bull World Health Org 73 1 (1995) 33-40
8. PAHO. Vigilancia de la Poliomielitis en las Américas. Boletin Semanal de Poliomielitis 18 1 (2003)
9. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., and Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59 (2005) 587-635
10. Aylward R.B., Sutter R.W., and Heymann D.L. Policy: OPV cessation-the final step to a "polio-free" world. Science 310 5748 (2005) 625-626
11. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 81 15 (2006) 137-144
12. Centro Latinoamericano de Perinatología y Desarrollo Humano (CLAP). OPS-OMS. 1994;1304.
13. Arya S.C., and Agarwal N. Poliomyelitis: concerns for polio-free countries. Vaccine 25 17 (2007) 3245-3246
14. Outbreak of type-1 wild poliovirus in adults, Namibia, 2006. Wkly Epidemiol Rec 81 45 (2006) 425-430
15. Nates S.V., Martinez L.C., Barril P.A., Ferreyra L.J., Giordano M.O., Masachessi G., et al. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously. Viral Immunol 20 1 (2007) 3-10
16. Bass J.W., Halstead S.B., Fischer G.W., Podgore J.K., and Wiebe R.A. Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series. JAMA 239 21 (1978) 2252-2255
17. Mastroeni I., Patti A.M., Fabrizi A., Santi A.L., Manduca A.M., Vescia N., et al. Immunity status against poliomyelitis in persons 13-14 years old living in Rome. Vaccine 15 6-7 (1997) 747-750
18. Reali D., Carducci A., and Ruschi M.A. Serum antibodies to polioviruses in a Tuscan population, Italy. Eur J Epidemiol 6 3 (1990) 309-312
19. Trivello R., Farisano G., Bonello C., Moschen M.E., Baldo V., Majori S., et al. Immunity status to poliovirus in Veneto region (north-east Italy). A seroepidemiological survey. Ann Clin Lab Sci 24 6 (1994) 542-547
20. Trivello R., Renzulli G., Farisano G., Bonello C., Moschen M., Gasparini V., et al. Persistence of poliovirus-neutralizing antibodies 2-6 years after immunization with live attenuated vaccine. A seroepidemiologic survey in the mainland of Venice. Epidemiol Infect 101 3 (1988) 605-609
21. Lamy M.E., Cornu C., and Desmyter J. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium. Dev Biol Stand 43 (1979) 207-213
22. Frantzidou F., Diza E., Halkia D., and Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbiol Infect 11 1 (2005) 68-71
23. Lapinleimu K., and Stenvik M. Experiences with polio vaccination and herd immunity in Finland. Dev Biol Stand 47 (1981) 241-246
24. Schoub B.D., Blackburn N.K., and McAnerney J.M. Seroprevalence to polio in personnel at a virology institute. J Infect 43 2 (2001) 128-131
25. Conclusions and recommendations of the Advisory Committee on Poliomyelitis eradication, Geneva, 11-12 October 2006, Part I. Wkly Epidemiol Rec 81 48 (2006) 453-460
26. The Sixty-first World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication. 2008;WHA61.1.
27. Ifekwunigwe A.E., Grasset N., Glass R., and Foster S. Immune responses to measles and smallpox vaccinations in malnourished children. Am J Clin Nutr 33 3 (1980) 621-624
28. Bahl R., Bhandari N., Kant S., Molbak K., Ostergaard E., and Bhan M.K. Effect of vitamin A administered at Expanded Program on Immunization contacts on antibody response to oral polio vaccine. Eur J Clin Nutr 56 4 (2002) 321-325
29. Caidi H., Bennis I.F., Mouan N., and El Aouad R. Evaluation of the response to vaccination against poliomyelitis and measles in malnourished children in Morocco. East Mediterr Health J 10 4-5 (2004) 474-481
30. World Health Organization. Immunization Profile-Uruguay. http://www.who.int/vaccines/globalsummary/immunization/countryprofilesel ect.cfm. [Last accessed 6.10.2008].
31. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 356 15 (2007) 1536-1544
32. Dayan G.H., Thorley M., Yamamura Y., Rodriguez N., McLaughlin S., Torres L.M., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 195 1 (2007) 12-20
33. Lagos R., Kotloff K., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 17 4 (1998) 294-304
34. Araujo O.O., Forleo-Neto E., Vespa G.N., Puccini R.F., Weckx L.W., Carvalho E.S., et al. Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type b (Hib) vaccine, a diphtheria-tetanus-whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib. Vaccine 19 2-3 (2000) 367-375
35. Bonnet M.C., and Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 26 39 (2008) 4978-4983
36. Renteria y Cárdenas A. La cartilla nacional de vacunación de México para 2007. Arch Invest Pediátr Méx 10 1 (2007) 3-4